Business

Seelos Therapeutics has announced an amendment of its agreement with Vyera Pharmaceuticals regarding development of SLS-002 intranasal ketamine. According to Seelos, the company will now not be required to conduct a Phase 3 trial and will make cash and stock payments to Vyera instead of a milestone that would be due on initiation of a Phase 3 trial. Seelos said … [Read more...] about Seelos Therapeutics says it has amended agreement for development of its intranasal ketamine

Bryn Pharma (formerly Epi-Now) announced that it has signed a deal with Aptar Pharma for worldwide exclusive rights to use Aptar's Bidose nasal delivery device for its BRYN-NDS1C intranasal epinephrine for the treatment of anaphylaxis. The company said that it has recently completed dosing in a pivotal clinical trial using the device. According to Bryn's website, … [Read more...] about Bryn Pharma to use Aptar’s Bidose nasal device for epinephrine delivery

Circassia Pharmaceuticals has announced the US launch of Duaklir aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The FDA approved Duaklir Pressair in April 2019. Circassia acquired the US rights to Duaklir and Tudorza Pressair from AstraZeneca in 2017. Circassia Chief Executive Steve Harris commented, “The US launch of Duaklir represents a … [Read more...] about Circassia announces US launch of Duaklir Pressair for the treatment of COPD

AZTherapies said that the company had closed a $26.3 million Series C preferred equity financing round that will fund completion of a Phase 3 trial of its ALZT-OP1 inhaled cromolyn/oral ibuprofen for the treatment of Alzheimer's disease. The COGNITE study was initiated in 2015 and is expected to be completed by the end of 2020. The company said that proceeds from … [Read more...] about AZTherapies raises $26.3 million in Series C financing

Respira Therapeutics has announced that United Therapeutics will end its collaboration with the company and will return all rights to Respira's RT234 vardenafil DPI, which is in Phase 2 development for the relief of symptoms of pulmonary arterial hypertension (PAH). The companies had announced the licensing deal and an investment by United Therapeutics in Respira in … [Read more...] about United Therapeutics returns rights to Respira’s RT234 vardenafil DPI

According to Vectura, the English High Court has dismissed all claims in a "passing off" case brought by GlaxoSmithKline in which GSK charged that of Sandoz's AirFluSal Forspiro DPI looks too similar to Seretide Accuhaler. Both inhalers and their packaging feature a similar shade of purple. Vectura noted that GSK has filed similar cases in a number of European … [Read more...] about English High Court dismisses GSK claims in AirFluSal Forspiro case

Lannett said that it has signed a US distribution agreement for rights to Respirent Pharmaceuticals' generic Advair Diskus. The agreement would begin after FDA approval and would continue for 10 years after distribution begins. Lannett said that it would pay an unspecified upfront payment and future milestones and that it would receive a portion of net profits during … [Read more...] about Lannett makes deal for distribution of generic Advair in US

Currax Pharmaceuticals has acquired US, Canadian, and Mexican rights to Onzetra Xsail intranasal dry powder sumatriptan from OptiNose, which announced that the license agreement includes a $4.8 million upfront payment, plus a 10% royalty on net sales over $3 million in 2020 and a $1 million milestone payment "subject to the achievement of a specified regulatory … [Read more...] about Currax Pharmaceuticals acquires North American rights to Onzetra Xsail